Amibegron

DB05395InvestigationalSmall molecule

Amibegron is an agonist for atypical beta3-adrenoceptors which inhibits intestinal motility.

Mechanism: SR 58611 has positive chronotropic effect which is mainly of peripheral origin and can be attributed to a baroreceptor-mediated reflex due to the beta3-adrenoceptor mediated vasodilation with an increase in sympathetic tone and a reduction in vagal tone to the heart.
Curator reviewed
Primary indication: Investigated for use/treatment in depression, irritable bowel syndrome (IBS), and obesity.Curator reviewed
Formula / weight: C₂₂H₂₆ClNO₄ · 403.9 g/mol (avg)
Code names: SR-58611

Resolves to

Compound

Structure

InChIKeyRDJQCOBTKKAQAH-FPOVZHCZSA-NSMILES[H][C@](O)(CN[C@@]1([H])CCC2=C(C1)C=C(OCC(=O)OCC)C=C2)C1=CC(Cl)=CC=C1

Targets

What you can answer from here — as of September 13, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

672Drug interactionsStructured to mechanism, not free text

5Clinical trialsPhase, status and sponsor resolved per trial

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with Amibegron, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.